Habiba Zafar

Habiba Zafar

Auto-generated profile, based on publicly available information

Habiba Zafar

Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
ARAhmed Asad Raza
Ahmed Asad Raza
GAGhazi Uddin Ahmed
Ghazi Uddin Ahmed
HZHabiba Zafar
Habiba Zafar
SASyed Owais Akhtar
Syed Owais Akhtar
MMMuhammad Bin Mobin
Muhammad Bin Mobin
ASAbedin Samadi
Abedin Samadi
Background: Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) are debilitating psychiatric conditions associated with significant psychosocial and economic burdens. Conventional antidepressants, particularly SSRIs and SNRIs, often produce inadequate responses and cause sexual dysfunction, contributing to poor adherence and diminished quality of life. Aim: This review aims to evaluate the clinical efficacy, safety, and sexual side effect profile of intranasal esketamine (Spravato) in the treatment of MDD and TRD, highlighting its potential advantages over traditional antidepressants. Methods: A narrative literature review was conducted using PubMed, ScienceDirect, Cochrane Library, and Google Scholar. Clinical trials, meta-analyses, and systematic reviews published between 2000 and 2025 were included. Keywords used included “Spravato”, “esketamine”, “treatment-resistant depression”, and “sexual dysfunction.”. Results: Clinical trials such as TRANSFORM-2, SUSTAIN-1, and ASPIRE I/II demonstrate that esketamine provides rapid antidepressant effects—often within hours—and improves remission and response rates in TRD. Its NMDA receptor antagonism promotes synaptogenesis and neuroplasticity, distinguishing it mechanistically from monoaminergic antidepressants. Compared to SSRIs/SNRIs, Spravato exhibits a significantly lower incidence of treatment-emergent sexual dysfunction (TESD), with less than 1% of patients reporting such side effects. However, the drug’s use is constrained by dissociative symptoms, blood pressure changes, and its mandatory in-clinic administration due to REMS (Risk Evaluation and Mitigation Strategy) requirements. Conclusion: Spravato (esketamine) is an innovative and effective treatment option for TRD and severe MDD, offering rapid symptom relief and a favorable sexual side effect profile. Despite logistical and financial limitations, it represents a critical advancement in personalized psychiatry, especially for patients unresponsive to conventional therapy.

22 April 2024 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
MMMuhammad Bin Mobin
Muhammad Bin Mobin
HZHabiba Zafar
Habiba Zafar
Review articles highlighting importance of various issues in the domain of public health, drug and medical education

23 September 2024 in International Journal of Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAmna Shakeel
Amna Shakeel
HZHabiba Zafar
Habiba Zafar
A recent study emphasized that about 1-2% of the general population is inflicted with body dysmorphic disorder (BDD), with a greater prevalence in women. Women demonstrate more distress associated with BBD, accompanied by repetitive behaviors related to their appearance, such as checking, camouflaging, or attempting to ‘improve’ the appearance of the perceived flaw by resorting to excessive grooming, cosmetic surgery, using makeup, wearing a costume mask, and often concealing the body part they find unappealing.